Telehealth as a Modality to Increase the Uptake of PrEP Services in Black and Latino: "e-PrEP"
e-PrEP
1 other identifier
interventional
75
1 country
3
Brief Summary
To evaluate if utilizing Telehealth medicine for access to HIV PrEP will engage more Black and Latino Men who have sex with Men (MSM)
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_4
Started Jul 2022
Typical duration for phase_4
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 19, 2022
CompletedStudy Start
First participant enrolled
July 19, 2022
CompletedFirst Posted
Study publicly available on registry
September 6, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
March 21, 2025
CompletedSeptember 23, 2025
September 1, 2025
2 years
May 19, 2022
September 18, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
: To increase the number and proportion of individuals who start PrEP who have been under-represented in PrEP uptake including those who identify as Black and/or Latino MSM.
Offer PrEP care via tele-health to reduce obstacles that clients have in coming to clinic.
18 months
Secondary Outcomes (2)
To increase the number and proportion of individuals who are still taking PrEP and engaged in care at the end of 6 months by 30% and remain HIV negative including those who identify as Black and/or Latino MSM.
18 months
To assess the acceptability and implementation of the intervention by both patients and clinic staff.
18 months
Study Arms (1)
Open Label Descovy
OTHERDescovy for PrEP
Interventions
Eligibility Criteria
You may qualify if:
- HIV negative on any FDA approved HIV test within 10 days of starting PrEP 18 years and older
- No medical or mental health comorbidity that would preclude participating in a clinical study as deemed by the study investigator
- Able to understand and sign consent in English or with other language interpreter
- Able to stay in the state catchment area of the license health care provider
- No use of PrEP for more than 30 days in the last year
You may not qualify if:
- HIV positive
- If greater and equal to 50 years of age and Renal Glomerular Filtration Rate (GFR) \<30 mg/g
- \<18 years of age
- No access to Internet or devise for telehealth
- Cis-gender Women
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Vivent Healthlead
- Gilead Sciencescollaborator
Study Sites (3)
Vivent Health
Denver, Colorado, 80245, United States
Vivent Health
St Louis, Missouri, 63103, United States
Viventh Health
Milwaukee, Wisconsin, 53203, United States
MeSH Terms
Interventions
Study Officials
- PRINCIPAL INVESTIGATOR
Cindy Firnhaber, MD
Vivent Health
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- NA
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
May 19, 2022
First Posted
September 6, 2022
Study Start
July 19, 2022
Primary Completion
July 31, 2024
Study Completion
March 21, 2025
Last Updated
September 23, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will not share